Clinical trial · Interventional
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase I/II, Multiple Center, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT06126237CI-TRIAL-00071240unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multi-center, open-label, Phase 1/2 study to evaluate the safety, tolerability, Pharmacokinetics, pharmacodynamics and Preliminary Efficacy of CM313 in Subjects with Relapsed or Refractory Multiple Myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CM313 injection | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- CM313
- description
- CM313 injection, subcutaneous
- interventionNames
- Biological: CM313 injection
- type
- EXPERIMENTAL
- label
- CM313 + concomitant medication
- description
- CM313 injection, subcutaneous
- interventionNames
- Biological: CM313 injection
Primary outcomes (1)
- measure
- Adverse event
- timeFrame
- up to 18 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects age ≥ 18 years. * Subjects diagnosed with multiple myeloma. * Subjects with measurable lesions. * Women of childbearing potential with negative pregnancy testing. * Subjects voluntarily signed the Informed Consent Form and were able to comply with the provisions of this protocol. Exclusion Criteria: * Previous treatment with any anti-CD38 therapy. * Vaccinated with live, attenuated vaccine within 4 weeks prior to the first dose. * Positive for human immunodeficiency virus (HIV) antibodies. * Syphilis antibody positive.
References
Publications (0)
Data not yet available
No reference posted for this study.